Excited to see the updated results from INDIGO confirming sustained benefit of mIDH inhibition for 1st line treatment in patients with G2 gliomas. Reduced seizure frequency aligns with our findings that mIDH inhibition modulates the glioma electrical microenvironment! 👇

A landmark research milestone, from a brilliant collaborative team, published in @natmed.nature.com 🔗 www.nature.com/articles/s41... @sarahannbest.bsky.social @saskiafreytag.bsky.social tag.bsky.social @jimwhittle.bsky.social

So incredibly proud of my team and our collaborators. What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors @braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social @wehi-research.bsky.social www.nature.com/articles/s41...

Researchers from WEHI, the Royal Melbourne Hospital & @petermaccc.bsky.social have achieved a brain cancer clinical trial world-first, providing hope to patients with low-grade gliomas. 🔗 www.wehi.edu.au/news/world-f...

A central question in neuro-oncology is whether therapies penetrate the tumour and exert a biological effect. @jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research. 1/8